Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Prevalence and outcomes of inherited and acquired thrombophilia in pediatric patients with venous thromboembolism: Findings from an institutional prospective inception cohort study

Evelyn Wooley, Maha Al-Ghafry, Anna Eidenberger et al. Nov 03, 2025 pp. 4913-4913 10.1182/blood-2025-4913

Abstract Background There has been a significant increase in pediatric VTE over the last two decades, particularly among hospitalized childr...

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Wei Zhang, Nan Xu, Hongfei Gu et al. Nov 03, 2025 pp. 4152-4152 10.1182/blood-2025-4152

Abstract BackgroundCAR-T cell therapy has demonstrated significant efficacy in B-cell malignancies, but relapse due to target antigen loss r...

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Amin Turki, Daniele Dall'Olio, Luciana Carota et al. Nov 03, 2025 pp. 451-451 10.1182/blood-2025-451

Abstract Introduction: In adults, acute myeloid leukemia (AML) is the most frequently diagnosed acute leukemia, yet with heterogeneous biolo...

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Bethan Hudson-Lund, Anandagopal Srinivasan, Eleanor Calcutt et al. Nov 03, 2025 pp. 2141-2141 10.1182/blood-2025-2141

Abstract Introduction Multiple myeloma has a complex transcriptomic landscape with gene mutations, fusions, and spliced...

De novo glycosylation of MHC class I in platelets

Li Guo, Yajing Zhao, Katy Gilham et al. Nov 03, 2025 pp. 1245-1245 10.1182/blood-2025-1245

Abstract Whether platelets can intracellularly de novo glycosylate proteins and how this affects platelet functions remains largely unknown....

In-hospital outcomes of patients admitted due to first-time acute chest syndrome with preexisting pulmonary embolism: A nationwide analysis 2016-2022

John Langley, Ben Lerman, Abdi Fite et al. Nov 03, 2025 pp. 1349-1349 10.1182/blood-2025-1349

Abstract Background: Acute chest syndrome (ACS) is a well-known complication in sickle cell disease with significant mor...

Real-world comparison of thrombotic events in patients with Myelodysplastic Syndromes treated with luspatercept versus erythropoietin-stimulating agents using trinetx database

Nikhil Vojjala, Syed Fahad Gillani, Raj Shah et al. Nov 03, 2025 pp. 22-22 10.1182/blood-2025-22

Abstract Background: Luspatercept, an erythroid maturation agent, has shown efficacy in improving anemia in both β-thalassemia and lower-ris...

Long-term projections of multiple myeloma mortality in the United States(2024-2040).: A time-series analysis stratified by sex, race, and geography

Abdullah Ahmad, Fiqe Khan, Bakhtawar Haseeb et al. Nov 03, 2025 pp. 7516-7516 10.1182/blood-2025-7516

Abstract Background:Multiple Myeloma remains as a hematologic malignancy with significant mortality burden and persistent demographic dispar...

Clonal timing of FLT3-ITD dictates evolutionary trajectory and phenotypic heterogeneity in acute myeloid leukemia

Xu-Dong He, Mengfang Xia, Ruoyang Shao et al. Nov 03, 2025 pp. 988-988 10.1182/blood-2025-988

Abstract Acute myeloid leukemia (AML) progresses through the sequential accumulation of somatic mutations, with signaling transducer mutatio...

Metabolism-focused CRISPR screen in B cell tumor identifies sphingolipid metabolism promotes resistance to CAR-T cell therapy

Qiqi Zhang, Ying Shen, Ruirui Jing et al. Nov 03, 2025 pp. 2320-2320 10.1182/blood-2025-2320

Abstract Significance Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed/refractory B-cell acute l...

Effect of immunoglobulin-replacement therapy on the incidence of severe infections in patients with chronic lymphocytic leukemia

Jiani Zhou, Elisabet Viayna, James Jordan et al. Nov 03, 2025 pp. 2729-2729 10.1182/blood-2025-2729

Abstract Introduction: Patients with chronic lymphocytic leukemia (CLL) are at increased risk of secondary hypogammaglobulinemia (HGG), whic...

Revolutionizing hematology/oncology education through visual storytelling and gamification for internal medicine residents

Cameron Smith, Nidhi Patel, Amy Dechet et al. Nov 03, 2025 pp. 4639-4639 10.1182/blood-2025-4639

Abstract Introduction: Hematology/oncology (heme/onc) is an often-overlooked specialty among internal medicine didactic curricula. In one re...

Bridging the gap: Global caregiver perspectives on awareness, motivators, and barriers to clinical trial participation in sickle cell disease

John James, Johnny Mahlangu, Raffaella Colombatti et al. Nov 03, 2025 pp. 2952-2952 10.1182/blood-2025-2952

Abstract ”≥Background: The generation of robust and widely applicable data from clinical trials for sickle cell disease (SCD) depends on rec...

Investigation of predictive markers of disease complications in children with sickle cell disease: Preliminary findings from a multicenter prospective inception cohort study

Marisol Betensky, Steven Bruzek, Grant Vestal et al. Nov 03, 2025 pp. 4746-4746 10.1182/blood-2025-4746

Abstract Background: Sickle cell disease (SCD) is a multi-system, life-threatening disorder that leads to a wide spectrum of clinical compli...

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Anna Candoni, Alfonso Piciocchi, Luana Fianchi et al. Nov 03, 2025 pp. 5102-5102 10.1182/blood-2025-5102

Abstract INTRODUCTION. Based on the results of the phase III study INO-VATE, Inotuzumab ozogamicin (INO) has been approved as single agent f...

Temporal trends and demographic patterns in Hodgkin and non-Hodgkin lymphoma mortality among u.s. adults: A CDC wonder study

Zauha Fawad Memon, Rehan Ishaque, Sibgha Fawad Memon et al. Nov 03, 2025 pp. 8039-8039 10.1182/blood-2025-8039

Abstract BACKGROUND: Hodgkin Lymphoma (HL) and non-Hodgkin lymphoma (NHL) are distinct malignancies that affect the lymphatic system, exhibi...

Low serum IgG at apheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR T-cell therapy for B-cell lymphoma

Daisuke Kaji, Tatsuro Hirao, Mika Kuno et al. Nov 03, 2025 pp. 5492-5492 10.1182/blood-2025-5492

Abstract Background: Infections account for approximately half of non-relapse mortality following CAR T-cell therapy. Most infections occur...

Association between sars-cov-2 infection, COVID-19 vaccines and immune thrombocytopenia in adults. a nationwide population-based study in France.

Margaux Lafaurie, Jérémy Zordan, Yoann Zadro et al. Nov 03, 2025 pp. 1325-1325 10.1182/blood-2025-1325

Abstract Introduction: Early in the pandemic and the vaccination campaign, cases of immune thrombocytopenia (ITP) occurring after SARS-CoV-2...

Integrated multiomics identifies inhibitors of apoptosis (IAPs) and death-inducing signaling complex (DISC) components as novel vulnerabilities to overcome immune evasion in TP53-inactivated Acute Myeloid Leukemia

Jordan Yong Ming Tan, Chuqi Wang, Clara Kai Ting Koh et al. Nov 03, 2025 pp. 386-386 10.1182/blood-2025-386

Abstract TP53-inactivated (TP53-mutant or deficient) acute myeloid leukemia (AML) is a biologically and clinically aggressive subtype associ...

T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials

Gowarishankar Palaniswamy, Anjani Cherukuri, Rayyan Sunasra et al. Nov 03, 2025 pp. 6868-6868 10.1182/blood-2025-6868

Abstract Introduction B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging malignancy, particularly in relapsed/refractory (R/R...

Distinct mTOR- and CDK1-regulated translation circuits sustain FLT3-mutated AML survival under therapy

Daniela Ortiz Chavez, Hae Park, Maxwell McCabe et al. Nov 03, 2025 pp. 5068-5068 10.1182/blood-2025-5068

Abstract Background Previously, we demonstrated that bone marrow stromal factors protect FLT3-mutant AML cells from FLT3...

Association between adolescent and young adult (AYA) age, acuity of illness at diagnosis, and clinical trial enrollment among patients with hematologic malignancies at a pediatric center

Joshua Muniz, Xu Ji, Tarun Jain et al. Nov 03, 2025 pp. 6291-6291 10.1182/blood-2025-6291

Abstract Background: Adolescent and young adult (AYA) patients with hematologic malignancies have inferior disease-free and overall survival...

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Pierre Peterlin, Maël Heiblig, Stéphane Morisset et al. Nov 03, 2025 pp. 1658-1658 10.1182/blood-2025-1658

Abstract Background: IDH1 mutations are found in 6-10% of acute myeloid leukemia (AML) cases. Ivosidenib (IVO), an oral mIDH1 inhibitor, is...

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study

Sonja Zweegman, Fredrik Schjesvold, Alessandra Larocca et al. Nov 03, 2025 pp. 4064-4064 10.1182/blood-2025-4064

Abstract Background and Significance . Novel treatments have considerably improved survival of transplant-ineligible patients with newly diag...

Renal responses in a phase 1/2 study of at-02, a novel pan-amyloid depleter ig fusion protein for the treatment of patients with AL amyloidosis

Gregory Bell, Claire Sherman, Matt Meldorf et al. Nov 03, 2025 pp. 693-693 10.1182/blood-2025-693

Abstract Introduction AT-02 is a humanized, recombinant IgG1 monoclonal antibody fusion protein containing a peptide tha...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page